Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03735979 · ClinicalTrials.gov registry record · Phase 3
Multi-arm Optimization of Stroke Thrombolysis
A Phase 3 study of Acute Ischemic Stroke, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 514
- Enrollment target
- 20
- Study locations
NCT03735979 is a Phase 3 study of Acute Ischemic Stroke that has completed, run by Washington University School of Medicine. The registered enrollment target is 514 participants, above the 331-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (55% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT03735979, a Phase 3 study of Acute Ischemic Stroke, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 514 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with standard of care thrombolysis (0.9mg/kg IV rt-PA or 0.25mg/kg IV tenecteplase or TNK) within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care. Time of onset is defined as the last time the patient was last known to be well.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Argatroban
- DRUG Eptifibatide
Study Locations (20)
California
- St. Jude Medical Center - Fullerton
- UCSD Health La Jolla - La Jolla
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- UC Irvine Medical Center - Orange
- UCSD Medical Center - Hillcrest Hospital - San Diego
- San Francisco General Hospital - San Francisco
- UCSF Medical Center - San Francisco
- Santa Barbara Cottage Hospital - Santa Barbara
Florida
- Baptist Medical Center Jacksonville - Jacksonville
- Mayo Clinic Hospital - Jacksonville
- Jackson Memorial Hospital - Miami
- Sarasota Memorial Hospital - Sarasota
- Tampa General Hospital - Tampa
Illinois
- University of Chicago Medical Center - Chicago
- Loyola University Medical Center - Maywood
- Javon Bea Hospital - Riverside - Rockford
Alabama
- University of Alabama Hospital - Birmingham
Connecticut
- Yale New Haven Hospital - New Haven
Georgia
- Grady Memorial Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 514 participants |
| Start Date | 2019-10-15 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03735979
The ClinicalTrials.gov registry entry for NCT03735979 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 514 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 331-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (55% higher). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03735979 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03735979 about?
NCT03735979 is a clinical study titled "Multi-arm Optimization of Stroke Thrombolysis". The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placeb...
What is the current status of trial NCT03735979?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 514 participants. The study started on 2019-10-15. Estimated completion is 2024-10-31.
What conditions does trial NCT03735979 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT03735979?
The interventions under investigation include: Placebo (DRUG), Argatroban (DRUG), Eptifibatide (DRUG).
Who is sponsoring clinical trial NCT03735979?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03735979 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
RECRUITING · Phase 3
-
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
RECRUITING · Phase 3
-
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
COMPLETED · Phase 3
-
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
COMPLETED · Phase 3
-
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
RECRUITING · Phase 2
-
Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.